Bejon Philip, Kai Oscar K, Mwacharo Jedidah, Keating Sheila, Lang Trudie, Gilbert Sarah C, Peshu Norbert, Marsh Kevin, Hill Adrian V S
Kenya Medical Research Institute, Centre for Geographical Medical Research (Coast), Kilifi, Kenya.
Eur J Immunol. 2006 Aug;36(8):2264-72. doi: 10.1002/eji.200636187.
A heterologous prime-boost strategy has been developed to potently induce T cell responses to pre-erythrocytic malaria antigens. Efficacy in the field is likely to depend on both peak immunogenicity and the durability of responses. To improve both immunogenicity and durability of responses, 54 adult males from a malaria endemic area were immunized with different vaccination regimens, systematically varying antigenic insert and the number and sequence of component vaccinations. The component vaccinations were recombinant attenuated viruses, either fowlpox (FP) 9 or modified vaccinia virus Ankara (MVA). These were recombinant for either of two pre-erythrocytic malaria antigens (multiple epitope-thrombospondin-related adhesion protein, ME-TRAP, or circumsporozoite antigen (CS). ELISPOT assays were used to measure the effector and resting memory T cell responses. Sequence, antigen insert and number of vaccinations influenced immunogenicity, but the novel alternating vector immunizations generated the largest resting memory T cell populations. Effector responses were maintained at 84% of the peak response after 270 days. This durability of response is unprecedented. Classical prime-boost vaccination responses were at 5% of the peak after 270 days. Vaccines administered by heterologous prime-boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development.
一种异源初免-加强策略已被开发出来,以有效诱导针对疟原虫前红细胞期抗原的T细胞反应。该策略在实际应用中的效果可能取决于峰值免疫原性和反应的持久性。为了提高反应的免疫原性和持久性,来自疟疾流行地区的54名成年男性接受了不同的疫苗接种方案,系统地改变抗原插入物以及组成疫苗接种的数量和顺序。组成疫苗接种是重组减毒病毒,即禽痘病毒(FP)9或安卡拉改良痘苗病毒(MVA)。这些病毒针对两种疟原虫前红细胞期抗原之一进行了重组(多表位-血小板反应蛋白相关黏附蛋白,ME-TRAP,或环子孢子虫抗原(CS))。采用酶联免疫斑点试验(ELISPOT)来测量效应性T细胞和静息记忆T细胞反应。接种顺序、抗原插入物和接种次数影响免疫原性,但新型交替载体免疫接种产生了最大的静息记忆T细胞群体。270天后,效应性反应维持在峰值反应的84%。这种反应的持久性是前所未有的。传统的初免-加强疫苗接种反应在270天后为峰值的5%。针对多种病原体和癌症正在开发采用异源初免-加强方案接种的疫苗。这些数据表明,在临床开发中,这些疫苗也应采用交替载体方案进行接种。